Drug Trial Radar · NCT07504588
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
87
Planned (sponsor's estimate)
Start
Sep 24, 2026
Primary completion
Apr 12, 2029
Study completion Apr 12, 2029
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Apr 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial response to platinum therapy (platinum-sensitive), that has progressed after poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor maintenance therapy (recurrent), and that has a mutation in the BRCA1 or BRCA2 genes or is homologous recombination deficient. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Giving sacituzumab govitecan and bevacizumab may kill more tumor cells than standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with recurrent platinum-sensitive ovarian cancers that have BRCA1/2 mutations or homologous recombination deficiency.
Conditions
- Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
- Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma
- Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma
- Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma
- Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma
- Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Anti-VEGF Monoclonal AntibodyBiological
Given IV
BevacizumabBiological
Given IV
Biospecimen CollectionProcedure
Undergo collection of blood samples
CarboplatinDrug
Given IV
Computed TomographyProcedure
Undergo CT
Echocardiography TestProcedure
Undergo ECHO
GemcitabineDrug
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
Multigated Acquisition ScanProcedure
Undergo MUGA
Pegylated Liposomal Doxorubicin HydrochlorideDrug
Given IV
Sacituzumab GovitecanBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survivalTime frame: From randomization to either progressive disease or death from any cause, assessed up to 5 years
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
Highlands Oncology Group - Fayetteville
Fayetteville, Arkansas · Recruiting
Highlands Oncology Group - Rogers
Rogers, Arkansas · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho · Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho · Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho · Recruiting
Carle at The Riverfront
Danville, Illinois · Recruiting
Carle Physician Group-Effingham
Effingham, Illinois · Recruiting
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois · Recruiting
Carle BroMenn Medical Center
Normal, Illinois · Recruiting
Carle Cancer Institute Normal
Normal, Illinois · Recruiting
Carle Cancer Center
Urbana, Illinois · Recruiting
Goshen Center for Cancer Care
Goshen, Indiana · Recruiting
Mercy Hospital
Cedar Rapids, Iowa · Recruiting
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa · Recruiting
Our Lady of the Lake Physician Group
Baton Rouge, Louisiana · Recruiting
Our Lady of the Lake Medical Oncology
Baton Rouge, Louisiana · Recruiting
Mercy Hospital Springfield
Springfield, Missouri · Recruiting
Community Hospital of Anaconda
Anaconda, Montana · Recruiting
Billings Clinic Cancer Center
Billings, Montana · Recruiting
Bozeman Health Deaconess Hospital
Bozeman, Montana · Recruiting
Benefis Sletten Cancer Institute
Great Falls, Montana · Recruiting
Logan Health Medical Center
Kalispell, Montana · Recruiting
Community Medical Center
Missoula, Montana · Recruiting
Monmouth Medical Center
Long Branch, New Jersey · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
Community Medical Center
Toms River, New Jersey · Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma · Recruiting
University of Virginia Cancer Center
Charlottesville, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.